2 weeks Ago By ABMN Staff
Rhumbline Advisers raised its stake in shares of Q32 Bio Inc. ( NASDAQ:QTTB – Free Report ) by 11,681.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
The fund owned 7,658 shares of the company’s stock after purchasing an additional 7,593 shares during the quarter. Rhumbline Advisers’ holdings in Q32 Bio were worth $137,000 as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other hedge funds and other institutional investors have also bought and sold shares of QTTB.
Acadian Asset Management LLC bought a new stake in Q32 Bio in the 1st quarter worth approximately $62,000. Bank of New York Mellon Corp purchased a new stake in Q32 Bio during the second quarter valued at about $315,000. Ikarian Capital LLC bought a new position in shares of Q32 Bio during the first quarter valued at about $381,000.
Affinity Asset Advisors LLC purchased a new position in shares of Q32 Bio in the first quarter worth about $473,000. Finally, Vanguard Group Inc. bought a new stake in shares of Q32 Bio in the 1st quarter valued at about $1,836,000.
Hedge funds and other institutional investors own 31.32% of the company’s stock. Q32 Bio Trading Up 1.
3 % NASDAQ QTTB opened at $46.00 on Monday. Q32 Bio Inc.
has a 12 month low of $8.24 and a 12 month high of $53.79.
The company has a debt-to-equity ratio of 0.37, a quick ratio of 6.49 and a current ratio of 6.
49. The business has a fifty day moving average of $40.60.
The stock has a market capitalization of $549.33 million, a PE ratio of -1.41 and a beta of -0.
32. Wall Street Analyst Weigh In Several research analysts have recently issued reports on the stock. Guggenheim began coverage on shares of Q32 Bio in a report on Monday, June 17th.
They issued a “buy” rating and a $100.00 target price on the stock. Wells Fargo & Company started coverage on shares of Q32 Bio in a report on Wednesday, September 11th.
They issued an “overweight” rating and a $95.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company.
According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $68.80.
View Our Latest Stock Report on QTTB Q32 Bio Company Profile ( Free Report ) Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. See Also Want to see what other hedge funds are holding QTTB? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Q32 Bio Inc. ( NASDAQ:QTTB – Free Report ). Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.
com's FREE daily email newsletter ..
